全文获取类型
收费全文 | 1242篇 |
免费 | 53篇 |
国内免费 | 12篇 |
专业分类
耳鼻咽喉 | 2篇 |
儿科学 | 28篇 |
妇产科学 | 16篇 |
基础医学 | 94篇 |
口腔科学 | 49篇 |
临床医学 | 81篇 |
内科学 | 430篇 |
皮肤病学 | 23篇 |
神经病学 | 109篇 |
特种医学 | 37篇 |
外科学 | 143篇 |
综合类 | 1篇 |
预防医学 | 41篇 |
眼科学 | 5篇 |
药学 | 73篇 |
肿瘤学 | 175篇 |
出版年
2023年 | 13篇 |
2022年 | 9篇 |
2021年 | 21篇 |
2020年 | 17篇 |
2019年 | 22篇 |
2018年 | 45篇 |
2017年 | 26篇 |
2016年 | 37篇 |
2015年 | 31篇 |
2014年 | 58篇 |
2013年 | 75篇 |
2012年 | 95篇 |
2011年 | 89篇 |
2010年 | 60篇 |
2009年 | 58篇 |
2008年 | 81篇 |
2007年 | 82篇 |
2006年 | 85篇 |
2005年 | 83篇 |
2004年 | 57篇 |
2003年 | 63篇 |
2002年 | 60篇 |
2001年 | 5篇 |
2000年 | 8篇 |
1999年 | 8篇 |
1998年 | 11篇 |
1997年 | 7篇 |
1996年 | 11篇 |
1995年 | 8篇 |
1994年 | 10篇 |
1993年 | 4篇 |
1992年 | 4篇 |
1991年 | 6篇 |
1990年 | 6篇 |
1989年 | 6篇 |
1988年 | 2篇 |
1987年 | 4篇 |
1986年 | 1篇 |
1985年 | 7篇 |
1984年 | 11篇 |
1983年 | 6篇 |
1982年 | 4篇 |
1981年 | 1篇 |
1978年 | 3篇 |
1977年 | 1篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1973年 | 1篇 |
1972年 | 1篇 |
1971年 | 1篇 |
排序方式: 共有1307条查询结果,搜索用时 12 毫秒
1.
Gordon Nicole T. Alberty-Oller Jaime J. Fei Kezhen Greco Giampaolo Gallagher Emily J. LeRoith Derek Feldman Sheldon M. Killilea Bridgid Boolbol Susan K. Choi Lydia Friedman Neil Pilewskie Melissa Port Elisa Tiersten Amy Bickell Nina A. 《Annals of surgical oncology》2021,28(11):5941-5947
Annals of Surgical Oncology - Black women with breast cancer have a worse overall survival compared with White women; however, no difference in Oncotype DX? (ODX) recurrence scores has been... 相似文献
2.
The authors describe a series of surgical approaches that they found particularly useful for the exposure and removal of lesions involving the skull base. These are: 1) fronto-naso-orbital approach; 2) frontotemporo-orbito-zygomatic approach; 3) subtemporal transpetrosal approach; 4) temporo-suboccipital transpetrosal approach (retrolabyrinthine presigmoid; transsigmoid; translabyrintine amend transcochlear presigmoid); 5) dorsolateral approach to the foramen magnum and lower clivus.As the approaches are complex and carry potential risks of morbidity, not only it is important to have a good knowledge of basic anatomy but also to closely follow the indications for each one. In this type of surgery where it is often difficult to achieve complete removal of the lesion by a single route of attack, more than one approach may be employed in different surgical steps. Finally, all these approaches demand extremely scrupulos surgical reconstruction to avoid dangerous postoperative complications that may jeopardize the previous work of the surgeon. 相似文献
3.
Mandruzzato G Antsaklis A Botet F Chervenak FA Figueras F Grunebaum A Puerto B Skupski D Stanojevic M;WAPM 《Journal of perinatal medicine》2008,36(4):277-281
Perinatal mortality and morbidity is markedly increased in intrauterine growth restricted (IUGR) fetuses. Prenatal identification of IUGR is the first step in clinical management. For that purpose a uniform definition and criteria are required. The etiology of IUGR is multifactorial and whenever possible it should be assessed. When the cause is of placental origin, it is possible to identify the affected fetuses. The major complication is chronic fetal hypoxemia. By monitoring the changes of fetal vital functions it is thus possible to improve both management and outcome. The timing of delivery is crucial but the optimal management scheme has not yet been identified. When IUGR is identified at very early gestational ages, serial assessments of the risk of continuing the in utero fetal life under adverse conditions versus the risks of the prematurity should be performed. Delivery of IUGR fetuses should take place in centers where appropriate neonatal assistance can be provided. Careful monitoring of the IUGR fetus during labor is crucial as the IUGR fetus can quickly decompensate once uterine contractions have started. 相似文献
4.
5.
Giant prolactinomas presenting as skull base tumors 总被引:2,自引:0,他引:2
Minniti G Jaffrain-Rea ML Santoro A Esposito V Ferrante L Delfini R Cantore G 《Surgical neurology》2002,57(2):99-103; discussion 103-4
BACKGROUND: Prolactinomas invading the skull base are rare, and could easily be confused with skull base tumors of nonpituitary origin. CASE DESCRIPTION: We report a series of 4 cases of giant prolactinomas invading the skull base and presenting with atypical symptoms. Case 1 presented with a short history of headache and nasal obstruction. Case 2 presented with progressive hypoacusia, dizziness, and ophthalmoplegia. In Case 3, the patient developed rapid progressive visual failure and psychiatric symptoms. Case 4 presented with a 1-year history of headache and retrorbital pain. The diagnosis of prolactinoma was made on the basis of tumor immunohistochemistry and/or high plasma prolactin levels (range from 650-6,500 ng/mL). Medical treatment with the dopamine agonist cabergoline was given; it was effective in normalizing prolactin levels and inducing tumor shrinkage. CONCLUSION: Prolactin levels should be measured in all large skull base tumors involving the pituitary region before any surgery or inappropriate radiotherapy is performed. 相似文献
6.
The initial management of nonfunctioning pituitary macroadenomas (NFAs) is usually surgery; however, a significant proportion
of NFAs may require further treatment. Radiotherapy is currently used in patients with residual tumour and achieves excellent
long-term control, but there are concerns about potential late toxicity. Stereotactic radiotherapy, both in the form of radiosurgery
or fractionated stereotactic radiotherapy, has been developed as a more accurate technique of irradiation with more precise
tumour localization and consequently a reduction in the volume of normal tissue, particularly the brain, irradiated to high
radiation doses. A review of the literature suggests that new radiation techniques offer safe and effective treatment for
recurrent or residual pituitary adenomas; however longer follow-up is necessary to confirm the excellent tumour control and
the potential reduction of long-term radiation toxicity. Currently, radiotherapy has an important role in patients with residual
or progressive disease after surgery. Patients with small or no residual tumours after surgery may generally continue on a
policy of surveillance without immediate irradiation, in order to avoid the potential toxicity of treatment. 相似文献
7.
Vincenzo Bottino Maria Grazia Esposito Arianna Mottola Giampaolo Marte Vittorio Di Maio Valerio Sciascia Marco Nunziante Giovanni Fregola Salvatore Cuzzovaglia Francesco Galante Federica Andreoli Alfredo Breglia Maria Elena Giuliano Domenico Papaleo Paola Della Rocca Pietro Maida 《BMC surgery》2012,12(Z1):S8
Background
The aim of this study was to define any benefits in terms of early outcome for laparoscopic colectomy in patients over 75 years old (OP) compared with the outcomes of a younger populations (YP).Methods
Forty elderly patients undergoing laparoscopic colectomy for colorectal cancer between 2007-2011 were studied, the patients are divided for gender, age, year of surgery, site of cancer, and comorbidity on admission and compared with 40 younger patients.Results and discussion
Mean (standard deviation) age was 81.3 in OP and 68.3 YP Conversion rate was the same between the two groups. There was no difference in operative mean time . The overall mortality rate was 0% percent. The surgical morbidity rate was the same but there was an increased in cardiologic e bronchopneumonia complications in older population. Patients treated with laparoscopic approach had a faster recovery of bowel function and a significant reduction of the mean length of hospital stay not age related. Laparoscopy allowed a better preservation of postoperative independence status.Conclusions
Laparoscopic colectomy for cancer in elderly patients is safe and beneficial including preservation of postoperative independence and a reduction of length of hospital stay.8.
Simple Enucleation Versus Radical Nephrectomy in the Treatment of pT1a and pT1b Renal Cell Carcinoma
Minervini A Serni S Tuccio A Siena G Vittori G Masieri L Giancane S Lanciotti M Khorrami S Lapini A Carini M 《Annals of surgical oncology》2012,19(2):694-700
Background
Simple tumor enucleation (TE) showed excellent oncologic results in large retrospective series. No study has compared oncologic outcomes after TE and radical nephrectomy (RN) for the treatment of pT1 renal cell carcinoma (RCC). The aim of the present study is to compare the oncologic outcomes after TE and RN in pT1 RCCs.Methods
We retrospectively analyzed 475 patients who underwent TE or RN for pT1 RCC, N0, M0, between 1995 and 2007. TE was performed in 332 patients and RN in 143. Local recurrence, progression-free survival (PFS), and cancer-specific survival (CSS) were the main outcomes of this study. The Kaplan-Meier method was used to calculate survival functions, and differences were assessed with the log rank statistic. Univariate and multivariate Cox regression models were also used.Results
The 5- and 10-year PFS estimates were 91.3 and 88.7% after RN and 95.3 and 92.8% after TE (P?=?NS), respectively. The 5- and 10-year CSS estimates were 92.1 and 89.4% after RN and 94.4% (5- and 10-year CSS) after TE (P?=?NS), respectively. No statistically significant differences between RN and TE were found after adjusting CSS probabilities according to age at surgery, grade, stage, or clear cell subtype. Surgical treatment was not a predictor of PFS or CSS by both univariate and multivariate analyses. The potential limitation of this study is that the data originate from a retrospective review.Conclusions
TE can achieve oncologic results similar to those of RN for the treatment of pT1 RCCs, provided tumors are carefully selected on the basis of their safe and complete removal. 相似文献9.
Valgimigli M Campo G Percoco G Bolognese L Vassanelli C Colangelo S de Cesare N Rodriguez AE Ferrario M Moreno R Piva T Sheiban I Pasquetto G Prati F Nazzaro MS Parrinello G Ferrari R;Multicentre Evaluation of Single High-Dose Bolus Tirofiban vs Abciximab With Sirolimus-Eluting Stent or Bare Metal Stent in Acute Myocardial Infarction Study 《JAMA》2008,299(15):1788-1799
Context Abciximab infusion and uncoated-stent implantation is a complementary treatment strategy to reduce major adverse cardiac events in patients undergoing angioplasty for ST-segment elevation myocardial infarction (STEMI). It is uncertain whether there may be similar benefits in replacing abciximab with high-dose bolus tirofiban. Similarly, the use of drug-eluting stents in this patient population is currently discouraged because of conflicting results on efficacy reported in randomized trials and safety concerns reported by registries. Objective To evaluate the effect of high-dose bolus tirofiban and of sirolimus-eluting stents as compared with abciximab infusion and uncoated-stent implantation in patients with STEMI undergoing percutaneous coronary intervention. Design, Setting, and Patients An open-label, 2 x 2 factorial trial of 745 patients presenting with STEMI or new left bundle-branch block at 16 referral centers in Italy, Spain, and Argentina between October 2004 and April 2007. Interventions High-dose bolus tirofiban vs abciximab infusion and sirolimus-eluting stent vs uncoated stent implantation. Main Outcome Measures For drug comparison, at least 50% ST-segment elevation resolution at 90 minutes postintervention with a prespecified noninferiority margin of 9% difference (relative risk, 0.89); for stent comparison, the rate of major adverse cardiac events, defined as the composite of death from any cause, reinfarction, and clinically driven target-vessel revascularization within 8 months. Results ST-segment resolution occurred in 302 of 361 patients (83.6%) who had received abciximab infusion and 308 of 361 (85.3%) who had received tirofiban infusion (relative risk, 1.020; 97.5% confidence interval, 0.958-1.086; P < .001 for noninferiority). Ischemic and hemorrhagic outcomes were similar in the tirofiban and abciximab groups. At 8 months, major adverse cardiac events occurred in 54 patients (14.5%) with uncoated stents and 29 (7.8%) with sirolimus stents (P = .004), predominantly reflecting a reduction of revascularization rates (10.2% vs 3.2%). The incidence of stent thrombosis was similar in the 2 stent groups. Conclusions In patients with STEMI undergoing percutaneous coronary intervention, compared with abciximab, tirofiban therapy was associated with noninferior resolution of ST-segment elevation at 90 minutes following coronary intervention, whereas sirolimus-eluting stent implantation was associated with a significantly lower risk of major adverse cardiac events than uncoated stents within 8 months after intervention. Trial Registration clinicaltrials.gov Identifier: NCT00229515 相似文献